AMGN - AMGEN INC

369.53
1.930   0.522%

Share volume: 2,411,895
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$367.60
1.93
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 71%
Dept financing 43%
Liquidity 30%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.19%
1 Month
-1.67%
3 Months
15.04%
6 Months
31.89%
1 Year
13.75%
2 Year
35.43%
Key data
Stock price
$369.53
P/E Ratio 
22.70
DAY RANGE
$361.70 - $369.76
EPS 
$14.33
52 WEEK RANGE
$261.43 - $391.29
52 WEEK CHANGE
$12.88
MARKET CAP 
175.037 B
YIELD 
2.93%
SHARES OUTSTANDING 
539.068 M
DIVIDEND
$2.52
EX-DIVIDEND DATE
05-15-2026
NEXT EARNINGS DATE
08-05-2025
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,668,720
AVERAGE 30 VOLUME 
$2,805,516
Company detail
CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recent news